GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase (ACC) Inhibitor, Reduces Plasma Acylcarnitines in Patients with Nonalcoholic Steatohepatitis (NASH)

被引：0
|
作者：
Charlton, Michael R. [1 ]
Lai, Michelle [2 ,3 ]
Noureddin, Mazen [4 ]
Tarrant, Jacqueline M. [5 ]
Wang, Lulu [5 ]
Tuan Nguyen [5 ]
McColgan, Bryan John [5 ]
Chung, Chuhan [5 ]
Patterson, Scott D. [5 ]
Myers, Robert P. [5 ]
Mantry, Parvez [6 ]
Ruane, Peter J. [7 ]
Loomba, Rohit [8 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Harvard Med Sch, Boston, MA USA
[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[5] Gilead Sci Inc, Foster City, CA 94404 USA
[6] Methodist Dallas Med Ctr, Liver Inst & Intervent Radiol, Dallas, TX USA
[7] Ruane Clin Res, Los Angeles, CA USA
[8] Univ Calif San Diego, Div Gastroenterol, NAFLD Res Ctr, San Diego, CA 92103 USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1741
引用
收藏
页码：992A / 993A
页数：2
相关论文
共 37 条
  • [1] Characterization of changes in lipoprotein profiles of patients with nonalcoholic steatohepatitis treated with the acetyl-CoA carboxylase inhibitor GS-0976
    Mantry, P.
    Kayali, Z.
    Noureddin, M.
    Ruane, P.
    Mccolgan, B.
    Tarrant, J.
    Wang, L.
    Nguyen, T.
    Harting, E.
    Djedjos, S.
    Ray, A.
    Myers, R.
    Lai, M.
    Charlton, M.
    Lawitz, E.
    Harrison, S.
    Loomba, R.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S583 - S584
  • [2] GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
    Alkhouri, Naim
    Lawitz, Eric
    Noureddin, Mazen
    DeFronzo, Ralph
    Shulman, Gerald, I
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 135 - 141
  • [3] Association between Apolipoprotein C3 and Serum Triglycerides in Nonalcoholic Steatohepatitis (NASH) Patients Treated with the Acetyl-CoA Carboxylase (ACC) Inhibitor GS-0976
    Mantry, Parvez S.
    Kayali, Zeid
    Noureddin, Mazen
    Ruane, Peter J.
    McColgan, Bryan John
    Tarrant, Jacqueline M.
    Wang, Lulu
    Tuan Nguyen
    Harting, Eliza
    Chung, Chuhan
    Myers, Robert P.
    Patterson, Scott D.
    Lai, Michelle
    Charlton, Michael R.
    Lawitz, Eric J.
    Harrison, Stephen A.
    Loomba, Rohit
    HEPATOLOGY, 2018, 68 : 968A - 968A
  • [4] Acetyl-CoA carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
    Lawitz, Eric J.
    Coste, Angie
    Poordad, Fred
    Alkhouri, Naim
    Loo, Nicole
    McColgan, Bryan J.
    Tarrant, Jacqueline M.
    Nguyen, Tuan
    Han, Ling
    Chung, Chuhan
    Ray, Adrian S.
    McHutchison, John G.
    Subramanian, G. Mani
    Myers, Robert P.
    Middleton, Michael S.
    Sirlin, Claude
    Loomba, Rohit
    Nyangau, Edna
    Fitch, Mark
    Li, Kelvin
    Hellerstein, Marc
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (12) : 1983 - +
  • [5] PRELIMINARY EFFICACY AND SAFETY OF ACETYL-COA CARBOXYLASE (ACC) INHIBITOR GS-0976 IN PATENTS WITH COMPENSATED CIRRHOSIS DUE TO NASH
    Harrison, Stephen A.
    Noureddin, Mazen
    Herring, Robert
    Ruane, Peter J.
    McColgan, Bryan J.
    Natha, Macky
    Kirby, Brian
    Nelson, Cara
    Aguilar, Raul
    Jia, Catherine
    Subramanian, Mani
    Myers, Robert P.
    Middleton, Michael S.
    Sirlin, Claude B.
    Fitch, Mark
    Li, Kelvin
    Hellerstein, Marc
    Lawitz, Eric
    GASTROENTEROLOGY, 2018, 154 (06) : S1166 - S1166
  • [6] Preliminary efficacy and safety of acetyl-CoA carboxylase inhibitor GS-0976 in patients with compensated cirrhosis due to NASH
    Harrison, S.
    Noureddin, M.
    Herring, R., Jr.
    Ruane, P.
    Mccolgan, B.
    Kirby, B.
    Nelson, C.
    Schall, R. A.
    Jia, C.
    Subramanian, M.
    Myers, R.
    Middleton, M.
    Sirlin, C.
    Fitch, M.
    Li, K.
    Hellerstein, M.
    Lawitz, E.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S583 - S583
  • [7] The Pharmacokinetics of GS-0976, an Acetyl-CoA Carboxylase (ACC) Inhibitor, in Subjects with Mild, Moderate, and Severe Hepatic Impairment
    Nelson, Cara
    Weber, Elijah
    Yue, Mun Sang
    Millward, Victoria
    Qin, Ann R.
    Marbury, Thomas C.
    Lawitz, Eric J.
    Li, Georgia
    Myers, Robert P.
    Kirby, Brian
    HEPATOLOGY, 2018, 68 : 979A - 980A
  • [8] Plasma metabolites for de novo lipogenesis and pharmacodynamic activity of acetyl-CoA carboxylase inhibitor GS-0976
    Tarrant, Jacqueline
    Vimal, Mona
    Adam, Klaus-Peter
    Hauser, Deirdre
    Wan, Haibao
    Xu, Ren
    Kirby, Brian
    Nelson, Cara H.
    Ray, Adrian S.
    Wang, Ting
    Stiede, Kathryn
    Westlin, William F.
    Djedjos, Constantine S.
    McColgan, Bryan J.
    Patterson, Scott D.
    Nguyen, Tuan
    Myers, Robert P.
    HEPATOLOGY, 2017, 66 : 1157A - 1158A
  • [9] Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to significant improvements in MRI-PDFF in a phase 2, randomized, placebo-controlled trial of patients with NASH
    Loomba, Rohit
    Kayali, Zeid
    Noureddin, Mazen
    Ruane, Peter
    Lawitz, Eric
    Gitlin, Norman
    Bennett, Michael
    Harting, ElizaJing
    McColgan, Bryan J.
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John G.
    Middleton, Michael S.
    Sirlin, Claude B.
    Lai, Michelle
    Charlton, Michael R.
    Harrison, Stephen A.
    HEPATOLOGY, 2017, 66 (06) : 1260A - 1261A
  • [10] Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
    Lu, Ying
    Su, Xiaolan
    Zhao, Manyu
    Zhang, Qianru
    Liu, Chuang
    Lai, Qinhuai
    Wu, Sijia
    Fang, Aiping
    Yang, Jinliang
    Chen, Xiaoxin
    Yao, Yuqin
    PEERJ, 2019, 7
1234